EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism

Yihan Zhao, Fang Zhang, Simin Zhang, Xiaona Zhang, Leili Gao, Qian Ren, Xueyao Han, Linong Ji

Hormone and Metabolic Research · 01.12.2024 · 56 (12) · 839-844

DOI: 10.1055/a-2411-9426 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.12.2024. Verfasst von Yihan Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Denosumab, Hypercalcemia, Hyperparathyroidism, Primary. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Research and Development Fund of Peking University People's Hospital, Research and Development Fund of Peking University Peopleʼs Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Denosumab is a completely human monoclonal high-affinity antibody that binds to the nuclear factor kappa-B ligand (RANKL) and is widely used to treat osteoporosis. Furthermore, it can potentially lower serum calcium levels by inhibiting osteoclast activation and preventing bone calcium from being released into the blood. This review aimed to provide evidence of the efficacy and safety of denosumab in treating hypercalcemia in primary hyperparathyroidism (PHPT). PubMed and the Cochrane Library were searched for published studies that described denosumab for hypercalcemia management in PHPT. Data were extracted by two independent investigators and analyzed using SPSS 23. The risk of bias was assessed by NIH Quality Assessment Tool. In total, 161 patients with PHPT from 18 studies were included in this review. The average age was 61 (47–72) years and the highest serum calcium was 3.76 (3.11–4.20) mmol/l. We found that denosumab can effectively reduce the serum calcium level by a median reduction of 0.5 mmol/l within 3 days. Significant reduction was maintained for 14 days. The serum calcium-lowering effect weakened after one month. In conclusion, denosumab has a potential clinical value in treating hypercalcemia in patients with PHPT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabHypercalcemiaHyperparathyroidism, PrimaryHumansMiddle AgedAgedCalciumFemaleMale

Substanzen

DenosumabCalcium

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.

Förderung

  • Research and Development Fund of Peking University People's Hospital
  • Research and Development Fund of Peking University Peopleʼs Hospital

Zitieren

APA

Zhao, Y., Zhang, F., Zhang, S., Zhang, X., Gao, L., Ren, Q., Han, X., & Ji, L. (2024). Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism. Hormone and Metabolic Research, 56(12), 839-844. https://doi.org/10.1055/a-2411-9426

Vancouver

Zhao Y, Zhang F, Zhang S, Zhang X, Gao L, Ren Q, et al. Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism. Hormone and Metabolic Research. 2024;56(12):839-844. doi:10.1055/a-2411-9426

BibTeX
@article{Zhao2024,
  author = {Zhao, Yihan and Zhang, Fang and Zhang, Simin and Zhang, Xiaona and Gao, Leili and Ren, Qian and Han, Xueyao and Ji, Linong},
  title = {Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism},
  journal = {Hormone and Metabolic Research},
  year = {2024},
  volume = {56},
  number = {12},
  pages = {839--844},
  doi = {10.1055/a-2411-9426}
}
Kostenlos starten →